AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3–Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)

Autores de IIS La Fe

• Pau Montesinos Fernández

  Autor

Participantes ajenos a IIS La Fe

• Erba H.
• Vrhovac R.
• Patkowska E.
• Kim H.-J.
• Zak P.
• Wang P.-N.
• Mitov T.
• Hanyok J.
• Liu L.
• Benzohra A.
• Lesegretain A.
• Cortes J.
• Perl A.
• Sekeres M.
• Dombret H.
• Amadori S.
• Wang J.
• Levis M.
• Schlenk R.

Grupos

• Hematología y Hemoterapia

Abstract

Abstract no disponible

Keywords

• CD135 antigen; cytarabine; daunorubicin; idarubicin; placebo; quizartinib; acute myeloid leukemia; adult; age; aged; allogeneic hematopoietic stem cell transplantation; Article; confidence interval; controlled study; double blind procedure; drug withdrawal; female; hazard ratio; human; infection; leukemia remission; leukocyte count; major clinical study; male; multiple cycle treatment; overall survival; phase 3 clinical trial; QT prolongation; randomized controlled trial; recurrence free survival